Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Nov 02, 2015	YANCOPOULOS GEORGE Director, President and CSO	Director, President and CSO	Form 4	Bona fide gift	43,348	--	500,000
Nov 02, 2015	YANCOPOULOS GEORGE Director, President and CSO	Director, President and CSO	Form 4	Bona fide gift	43,348	--	612,936
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs	Director, EVP CSO & Pres Regn Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	45,463	$19.29	642,772
Nov 30, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	46,453	$58.19	925,131
Jan 05, 2005	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	46,666	--	134,332
Aug 16, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	46,925	$625.25	889,785
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	47,876	$262.43	1,145,062
Dec 13, 2018	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	48,192	$377.31	118,993
Dec 12, 2019	YANCOPOULOS GEORGE Director, President and CSO	Director, President and CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	49,405	$377.16	371,876
Aug 05, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	50,000	$600.06	937,483

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media